FDA has granted priority review for AbbVie’s investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 hepatitis C virus infection.
Santilli
FDA has granted priority review for AbbVie’s investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 hepatitis C virus infection.
The regimen consists of ABT-450/ritonavir co-formulated with ombitasvir (ABT-267), and dasabuvir (ABT-333) with or without RBV. The combination of 3 different mechanisms of action interrupts the hepatitis C virus replication process with the goal of optimizing sustained virologic response rates across different patient populations, according to a company press release.
“FDA’s acceptance of AbbVie's new drug application and granting a priority review for its all-oral regimen for treating adult patients infected with the hep C virus currently positions the company as runner-up in the $20 billion market to Gilead Sciences,” according to John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries.
The outlook for AbbVie as the second-largest participant is promising as its 3-drug regimen is estimated to reach $3 billion in sales, according to Santilli.
“However, AbbVie’s second place position in the market may be short-lived, as Merck has made an impact in the market with its combination drug entry,” he said.
An all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor is being tested by Merck to treat hepatitis C.
Last week, Merck purchased biopharmaceutical maker Idenix Pharmaceuticals to help strengthen its hep C drug portfolio.
“The hep C market appears to be heading to a price war as the market backlash to Gilead's $1,000-a-pill Sovaldi continues and Merck, AbbVie, and Bristol-Myers Squibb compete aggressively on pricing,” Santilli said.
For more on hep C go to:
Chronic hep C: More effective, better-tolerated therapies still needed, researchers say
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More